PCH
DNLI icon

Polar Capital Holdings’s Denali Therapeutics DNLI Stock Holding History

Polar Capital Holdings’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-452,669
Closed -$9.29M – 284
2024
Q1 		$9.29M Hold
452,669
– – 0.05% 205
2023
Q4 		$9.71M Sell
452,669
-554,417
-55% -$11M 0.06% 202
2023
Q3 		$20.8M Hold
1,007,086
– – 0.15% 139
2023
Q2 		$29.7M Buy
1,007,086
+502,086
+99% +$14.1M 0.2% 122
2023
Q1 		$11.6M Buy
+505,000
New +$13.9M 0.09% 179
2022
Q1 		– Sell
-53,835
Closed -$2.4K – 469
2021
Q4 		$2.4K Hold
53,835
– – 0.01% 291
2021
Q3 		$2.72K Buy
53,835
+5,037
+10% +$284K 0.01% 296
2021
Q2 		$3.83K Buy
+48,798
New +$3.02M 0.02% 292

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return